<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03506243</url>
  </required_header>
  <id_info>
    <org_study_id>TG1409CPL</org_study_id>
    <nct_id>NCT03506243</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Study of Comparing Follitrope Versus Gonal-f in Chinese Infertility Women.</brief_title>
  <official_title>A Phase III, Multicenter, Blinded, Randomized, Controlled, Parallel, Comparative Study for the Evaluation of Safety and Efficacy of rhFSH Injection Compared With Gonal-F® Pen Undergoing Controlled Ovarian Hyper Stimulation IVF-ET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hangzhou YuYuan Bioscience Technology Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hangzhou YuYuan Bioscience Technology Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This study is for evaluating safety and efficacy of Recombinant human follicle-stimulating&#xD;
      hormone (Follitrope) injection compared with Gonal-F® Pen undergoing controlled ovarian hyper&#xD;
      stimulation in vitro fertilization - embryo transfer (IVF-ET) in China&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, multicenter, blinded, randomized, controlled, parallel, comparative study&#xD;
      for the evaluation of safety and efficacy of Recombinant human follicle-stimulating hormone&#xD;
      injection (Follitrope) compared with Gonal-F® Pen undergoing controlled ovarian hyper&#xD;
      stimulation in vitro fertilization - embryo transfer (IVF-ET) in China.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The total number of oocytes retrieved</measure>
    <time_frame>15 days after using FSH</time_frame>
    <description>The total number of oocytes retrieved</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total dose and duration of FSH administration</measure>
    <time_frame>Throughout the study completion (e.g., 10 days)</time_frame>
    <description>Total dose and duration of FSH administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No. of follicles with diameter equal or more than 14 mm on hGH injection day</measure>
    <time_frame>The day of hGH injection</time_frame>
    <description>No. of follicles with diameter equal or more than 14 mm on hGH injection day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No. of embryo transferred</measure>
    <time_frame>3 days after the ovum pick-up</time_frame>
    <description>No. of embryo transferred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>5 weeks after the embryo transfer</time_frame>
    <description>Clinical pregnancy rate by g-sac</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>On-going pregnancy rate</measure>
    <time_frame>10 weeks after the embryo transfer</time_frame>
    <description>On-going pregnancy rate by fetal heart-beat</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">451</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Follitrope PFS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gonal-F pen</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Follitrope PFS</intervention_name>
    <description>Follitrope PFS</description>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gonal-f pen</intervention_name>
    <description>Gonal-f pen</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Infertile adult women between 20 and 39 years at screening.&#xD;
&#xD;
          2. Infertile adult women with regular menstrual cycles of 25 to 35 days at screening.&#xD;
&#xD;
          3. Normal basal serum FSH, LH, E2, and P levels at the early follicular phase at&#xD;
             screening.&#xD;
&#xD;
          4. If the cause of infertility is due to following reasons:&#xD;
&#xD;
               -  Tubal factor&#xD;
&#xD;
               -  Unknown reason&#xD;
&#xD;
               -  Male infertility&#xD;
&#xD;
               -  Combined factors&#xD;
&#xD;
          5. Willing to give voluntary written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a clinically significant systemic disease, endocrine or metabolic&#xD;
             abnormalities.&#xD;
&#xD;
          2. Body Mass Index &gt; 30 (BMI; kg/m2) at screening.&#xD;
&#xD;
          3. Patients with a uterine (fibroids (diameter greater than or equal to 2CM endometrium),&#xD;
             endometrial polyps, intrauterine adhesions, uterine malformations), ovaries&#xD;
             (polycystic ovary, ovarian cysts) or adnexa (hydrosalpinx) abnormalities at screening.&#xD;
&#xD;
          4. patients with uterine, ovarian surgery treatment&#xD;
&#xD;
          5. Patients who experienced of severe ovarian hyperstimulation symptoms (OHSS) in&#xD;
             previous IVF cycles.&#xD;
&#xD;
          6. Patients who have shown poor response with gonadotropin hormone therapy.&#xD;
&#xD;
             *At least two of the following three features must be present:&#xD;
&#xD;
             ① A previous POR(≤3 retrieved oocyte with a conventional stimulation protocol)&#xD;
&#xD;
             ② An abnormal ovarian reserve test (i.e. AFC &lt; 5 follicles) at screening.&#xD;
&#xD;
          7. Abnormal metrorrhagia due to unknown reason at screening.&#xD;
&#xD;
          8. At least one of husband and wife to accept donor sperm or donor eggs or PGD subject&#xD;
&#xD;
          9. Subjects who are positive for HIV or syphilis at screening.&#xD;
&#xD;
         10. Significant known psychiatric disorder or who unable to understand the objectives and&#xD;
             methods, etc. of this clinical trial and unable to comply with the study procedures at&#xD;
             screening.&#xD;
&#xD;
         11. Presence of elicit alcohol, smoke or drug abuse habit at screening.&#xD;
&#xD;
         12. History of hypersensitivity to rhFSH or other pharmaceutical excipients of this drug.&#xD;
&#xD;
         13. Participation in any other clinical trial after registering for this study or have&#xD;
             participated in another clinical study within 3 month before randomization in this&#xD;
             study.&#xD;
&#xD;
         14. History of tumors of the ovary, breast, uterus, hypothalamus or pituary gland.&#xD;
&#xD;
         15. More than 3 times previously consecutive unsuccessful in vitro fertilization cycles at&#xD;
             screening.&#xD;
&#xD;
         16. Subjects with no clomiphene citrate or gonadotropin treatment within 1 month before&#xD;
             randomization.&#xD;
&#xD;
         17. Positive serum pregnancy test at screening.&#xD;
&#xD;
         18. 14 ± 2 days after the demotion, results of subjects who does not belong to the&#xD;
             standard (antral follicle size ≥10mm)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Pu Sun</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hangzhou Yuyuan Bioscience Technology Co.,Ltd</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310018</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2018</study_first_posted>
  <last_update_submitted>April 22, 2018</last_update_submitted>
  <last_update_submitted_qc>April 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IVF, rhFSH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

